New King’s College London research sheds light on the cellular mechanisms which enable cancer cells to escape the prostate and spread to other parts of the body.

Published in the journal Oncogene, the findings suggest that it may one day be possible to therapeutically disrupt the ‘homing signal’ which causes prostate cancer cells to enter the bloodstream and form secondary tumours.

Clinicians are currently unable to predict which prostate tumours will become metastatic and establish secondary tumours in other tissues, and which ones will remain within the prostate. Identifying a molecular pathway that contributes to this process could guide treatment by helping clinicians distinguish between the two forms of cancer, and it could also assist with singling out targets for therapeutic intervention.

A team of scientists and clinicians from King’s College London’s Centre for Developmental Neurobiology at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), and the University of Oxford, examined the cellular machinery of benign and malignant human prostate tissue and human prostate cancer cell lines.

They discovered a molecular pathway that organises the cytoskeleton and enables cells to respond to homing signals and invade other tissue outside the prostate. At the core of this pathway are two proteins called drebrin and EB3, which control the movement of cells through the outer layer of the prostate and into the bloodstream or lymphatic system.

Senior author of the study, Professor Phillip Gordon–Weeks from the Centre for Developmental Neurobiology at the IoPPN, King’s College London, said: ‘Prostate cancer cells are attracted to the tissue they invade by homing signals released from these tissues. We’ve now identified the cellular machinery that guides this process and we think these homing signals could one day be disrupted therapeutically to stop cancer cells escaping the primary tumour and invading the body to form secondary tumours. ‘This research provides a really compelling example of how basic research can drive and inform translational research. Using animal models, we now need to examine how the prostate cancer homing signal could be manipulated using treatments.’